A method of relieving, alleviating or ameliorating breast cancer, lung cancer, skin cancer, esophageal cancer, prostate cancer, glioma or leukemia in a patient comprising the administration to a patient in need thereof, a pharmacologically effective amount of a butane bridge modified tetra-O-substituted nordihydroguaiaretic acid derivative compound (BB—Sb4N), having the following general structure (Formula VI), and its pharmaceutically acceptable salts:
- wherein each Z is selected from the group consisting of H, —CHO, —CN, —CH2CH3, —CH2Cl, —CH2Br and —CH2F;
- wherein Y is selected from the group consisting of:
- -A-R;
- —(CH2)xHal, where x is an integer of 1 to 10, and Hal is a halogen atom, namely any of chlorine, fluorine, bromine or iodine;
- —(CH2CH2O)yH, where y is an integer of 1 to 10;
- and a carbamate-bonded group selected from the group consisting of:
- where n is an integer of 1 to 6, T1 is a saturated linear hydrocarbon chain of 2-6 carbons and optionally 1-3 halogen atoms, T2 is a 5- to 7-member ring optionally containing 0-3 double bonds and optionally containing 1-3 atoms of any of O, N and S, and T3 is methyl or ethyl;
- wherein when Y is -A-R, R is selected from an end group:
- a 5- to 7-member carbocyclic ring selected from the group consisting of a fully saturated ring with 1 to 3 N, O or S heteroatoms;
- a ring containing 1 to 3 double bonds for a 6- or 7-member ring and 1 to 2 double bonds for a 5-member ring, with 1 to 3 N, O or S heteroatoms for the 5 to 7 member ring;
- a ring containing a carbamate bond, a urea bond, a carbonate bond or an amide bond;
- and
- a water soluble group selected from the group consisting of an alkali metal salt of sulfonic acid;
- a pharmaceutically acceptable salt;
- a sugar and a polyhydroxy group;
- and
- A is a linear saturated hydrocarbon side chain with optional heteroatoms that is bonded at one end to the respective hydroxy residue O groups by an ether bond or a carbamate bond and at the other end to a carbon or a heteroatom in R.